Diagnosis and Treatment of Primary Aldosteronism in 2017: Did We Achieve Our Goals?

Martin Reincke; Tracy Ann Williams; Felix Beuschlein

doi:10.1055/s-0043-122145

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2017; 49(12): 905-907
DOI: 10.1055/s-0043-122145

Editorial

Diagnosis and Treatment of Primary Aldosteronism in 2017: Did We Achieve Our Goals?

Martin Reincke

¹Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany

,

Tracy Ann Williams

¹Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany

²Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Turin, Italy

,

Felix Beuschlein

¹Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany

³Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland

References
1 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young Jr. WF. The management of primary aldosteronism: Case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
2 Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A. Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J 2011; 58: 711-721
3 Amar L, Baguet JP, Bardet S, Chaffanjon P, Chamontin B, Douillard C, Durieux P, Girerd X, Gosse P, Hernigou A, Herpin D, Houillier P, Jeunemaitre X, Joffre F, Kraimps JL, Lefebvre H, Ménégaux F, Mounier-Véhier C, Nussberger J, Pagny JY, Pechère A, Plouin PF, Reznik Y, Steichen O, Tabarin A, Zennaro MC, Zinzindohoue F, Chabre O. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook. Ann Endocrinol (Paris) 2016; 77: 179-186
4 Iacobellis G, Petramala L, Marinelli C, Calvieri C, Zinnamosca L, Concistrè A, Iannucci G, De Toma G, Letizia C. Epicardial fat thickness and primary aldosteronism. Horm Metab Res 2016; 48: 238-241
5 Remde H, Hanslik G, Rayes N, Quinkler M. Glucose Metabolism in primary aldosteronism. Horm Metab Res 2015; 47: 987-993
6 Asbach E, Bekeran M, Reincke M. Parathyroid gland function in primary aldosteronism. Horm Metab Res 2015; 47: 994-999
7 Catena C, Colussi G, Brosolo G, Novello M, Sechi LA. Aldosterone and left ventricular remodeling. Horm Metab Res 2015; 47: 981-986
8 Sechi LA, Colussi GL, Novello M, Uzzau A, Catena C. Mineralocorticoid receptor antagonists and clinical outcomes in primary aldosteronism: As good as surgery?. Horm Metab Res 2015; 47: 1000-1006
9 Funder JW. Primary aldosteronism: New answers, new questions. Horm Metab Res 2015; 47: 935-940
10 Reincke M, Beuschlein F, Bidlingmaier M, Funder JW, Bornstein SR. Progress in primary aldosteronism. Horm Metab Res 2010; 42: 371-373
11 Reincke M, Funder JW, Zennaro MC, Beuschlein F. Progress in primary aldosteronism 2. Horm Metab Res 2012; 44: 155-156
12 Reincke M, Beuschlein F. Progress in primary aldosteronism: Translation on the move. Horm Metab Res 2015; 47: 933-934
13 Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. Eur J Endocrinol 2015; 172: R23-R30
14 Williams TA, JWM Lenders, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young Jr WF, Gomez-Sanchez CE, Funder JW, Reincke M. Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohor. Lancet Diabetes Endocrinol 2017; 5: 689-699
15 Buffolo F, Monticone S, Burrello J, Tetti M, Veglio F, Williams TA, Mulatero P. Is primary aldosteronism still largely unrecognized?. Horm Metab Res 2017; 49: 908-914
16 Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-1820
17 Stowasser M, Ahmed A, Guo Z, Wolley M, Ungerer J, McWhinney B, Poglitsch M, Gordon R. Can screening and confirmatory testing in the management of patients with primary aldosteronism be improved?. Horm Metab Res 2017; 49: 915-921
18 Lenders JW, Eisenhofer G, Reincke M. Subtyping of patients with primary aldosteronism: an update. Horm Metab Res 2017; 49: 922-928
19 Beuschlein F, Mulatero P, Asbach E, Monticone S, Catena C, Sechi LA, Stowasser M. The SPARTACUS trial: controversies and unresolved issues. Horm Metab Res 2017; 49: 936-942
20 Naruse M, Umakoshi H, Tsuiki M, Yokomoto M, Tagami T, Tanabe A, Shimatsu A. The latest developments of functional molecular imaging in the diagnosis of primary aldosteronism. Horm Metab Res 2017; 49: 929-935
21 Velema MS, de Nooijer AH, Burgers VW, Hermus AR, Timmers HJ, Lenders JW, Husson O, Deinum J. Health-related quality of life and mental health in primary aldosteronism: a systematic review. Horm Metab Res 2017; 49: 943-950
22 Omata K, Tomlins SA, Rainey WE. Aldosterone-producing cell clusters in normal and pathological states. Horm Metab Res 2017; 49: 951-956
23 Gomez-Sanchez CE, Kuppusamy M, Reincke M, Williams TA. Disordered CYP11B2 expression in primary aldosteronism. Horm Metab Res 2017; 49: 957-962
24 Scholl UI. Unanswered questions in the genetic basis of primary aldosteronism. Horm Metab Res 2017; 49: 963-968
25 Asbach E, Williams TA, Reincke M. Recent Developments in Primary Aldosteronism. Exp Clin Endocrinol Diabetes 2016; 124: 335-341
26 Prejbisz A, Kołodziejczyk-Kruk S, Lenders JW, Januszewicz A. Primary aldosteronism and obstructive sleep apnea: is this a bidirectional relationship?. Horm Metab Res 2017; 49: 969-976
27 Funder JW. Primary aldosteronism: the next five years. Horm Metab Res 2017; 49: 977-983